Burkholderia cepacia complex – Risk, Testing & Mitigation
17 April 2020
(Duration : 65 mins)
DR. TONY CUNDELL
Microbiological Consulting LLC, Scarsdale, NY, USA
Dr Cundell will introduce the pharmaceutical industry concept of an objectionable organism, along with Burkholderia cepacia complex (BCC) and its leading position amongst objectionable organisms. He will also review some remarkable examples of B.cepacia contamination of non-sterile pharmaceuticals, and the consequences that befell some companies and the consumers of their products. Detection methods and identification strategies for BCC will be discussed, in the context of the requirements of the new USP Chapter 60 (official in December 2019). Lastly, Dr Cundell will review the compendial requirements for risk mitigation as it pertains to B.cepacia complex.
We will also be joined by Dr Megha BAJAJ, Global Solutions Manager for BIOBALL, who will briefly introduce applications of the new BIOBALL Burkholderia cepacia complex range of quantitative control strains.
The webinar will conclude with a Question & Answer session to address any matters of specific interest.